WO2020115095A3 - Procédés et compositions pour la prévention et/ou le traitement de l'ischémie et de la lésion d'ischémie-reperfusion - Google Patents

Procédés et compositions pour la prévention et/ou le traitement de l'ischémie et de la lésion d'ischémie-reperfusion Download PDF

Info

Publication number
WO2020115095A3
WO2020115095A3 PCT/EP2019/083597 EP2019083597W WO2020115095A3 WO 2020115095 A3 WO2020115095 A3 WO 2020115095A3 EP 2019083597 W EP2019083597 W EP 2019083597W WO 2020115095 A3 WO2020115095 A3 WO 2020115095A3
Authority
WO
WIPO (PCT)
Prior art keywords
ischemia
treatment
prevention
compositions
methods
Prior art date
Application number
PCT/EP2019/083597
Other languages
English (en)
Other versions
WO2020115095A2 (fr
Inventor
Lina Badimon Maestro
Judit CUBEDO RÀFOLS
Gemma VILAHUR GARCÍA
Original Assignee
Glycardial Diagnostics, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycardial Diagnostics, S.L. filed Critical Glycardial Diagnostics, S.L.
Priority to CN201980091267.7A priority Critical patent/CN113395994A/zh
Priority to EP19816630.8A priority patent/EP3890830A2/fr
Priority to JP2021531704A priority patent/JP2022510403A/ja
Publication of WO2020115095A2 publication Critical patent/WO2020115095A2/fr
Publication of WO2020115095A3 publication Critical patent/WO2020115095A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'Apo J-Glyc dans la prévention d'une lésion ischémique, et à la fois de l'Apo J-Glyc et de l'Apo J non Glyc dans le traitement d'une lésion ischémique et dans le traitement d'une lésion d'ischémie-reperfusion.
PCT/EP2019/083597 2018-12-05 2019-12-04 Procédés et compositions pour la prévention et/ou le traitement de l'ischémie et de la lésion d'ischémie-reperfusion WO2020115095A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201980091267.7A CN113395994A (zh) 2018-12-05 2019-12-04 用于预防和/或治疗缺血和治疗缺血/再灌注损伤的方法和组合物
EP19816630.8A EP3890830A2 (fr) 2018-12-05 2019-12-04 Procédés et compositions pour la prévention et/ou le traitement de l'ischémie et de la lésion d'ischémie-reperfusion
JP2021531704A JP2022510403A (ja) 2018-12-05 2019-12-04 虚血傷害および虚血再灌流傷害の予防および／または治療のための方法および組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382897.9 2018-12-05
EP18382897 2018-12-05

Publications (2)

Publication Number Publication Date
WO2020115095A2 WO2020115095A2 (fr) 2020-06-11
WO2020115095A3 true WO2020115095A3 (fr) 2020-07-23

Family

ID=64746472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/083597 WO2020115095A2 (fr) 2018-12-05 2019-12-04 Procédés et compositions pour la prévention et/ou le traitement de l'ischémie et de la lésion d'ischémie-reperfusion

Country Status (4)

Country Link
EP (1) EP3890830A2 (fr)
JP (1) JP2022510403A (fr)
CN (1) CN113395994A (fr)
WO (1) WO2020115095A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075837A2 (fr) * 2003-02-21 2004-09-10 Tanox, Inc. Procédés de traitement et de prévention des lésions tissulaires associées aux blessures par reperfusion ischémique
WO2007028053A2 (fr) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methodes de traitement et de prevention de troubles cardiaques
WO2016090002A1 (fr) * 2014-12-04 2016-06-09 Board Of Regents Of The University Of Texas System Clustérine recombinée et son utilisation dans le traitement et la prévention de maladies
EP3232200A1 (fr) * 2016-04-12 2017-10-18 Institut Catalá De Ciencies Cardiovasculars (ICCC) Procédés et kits pour le diagnostic et la stratification de risque de patients atteints d'ischémie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075837A2 (fr) * 2003-02-21 2004-09-10 Tanox, Inc. Procédés de traitement et de prévention des lésions tissulaires associées aux blessures par reperfusion ischémique
WO2007028053A2 (fr) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methodes de traitement et de prevention de troubles cardiaques
WO2016090002A1 (fr) * 2014-12-04 2016-06-09 Board Of Regents Of The University Of Texas System Clustérine recombinée et son utilisation dans le traitement et la prévention de maladies
EP3232200A1 (fr) * 2016-04-12 2017-10-18 Institut Catalá De Ciencies Cardiovasculars (ICCC) Procédés et kits pour le diagnostic et la stratification de risque de patients atteints d'ischémie

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOGLIO ELEONORA ET AL: "Exosomal clusterin, identified in the pericardial fluid, improves myocardial performance following MI through epicardial activation, enhanced arteriogenesis and reduced apoptosis", INTERNATIONAL JOURNAL OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 197, 14 June 2015 (2015-06-14), pages 333 - 347, XP029251832, ISSN: 0167-5273, DOI: 10.1016/J.IJCARD.2015.06.008 *
GUODONG LIU ET AL: "Clusterin Reduces Cold Ischemia-Reperfusion Injury in Heart Transplantation Through Regulation of NF-kB Signaling and Bax/Bcl-xL Expression", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY., vol. 45, no. 3, 1 January 2018 (2018-01-01), CH, pages 1003 - 1012, XP055585923, ISSN: 1015-8987, DOI: 10.1159/000487295 *
JUDIT CUBEDO ET AL: "Proteomic Signature of Apolipoprotein J in the Early Phase of New-Onset Myocardial Infarction", JOURNAL OF PROTEOME RESEARCH, vol. 10, no. 1, 7 January 2011 (2011-01-07), pages 211 - 220, XP055224821, ISSN: 1535-3893, DOI: 10.1021/pr100805h *
VAN DIJK ANNEMIEKE ET AL: "Intravenous clusterin administration reduces myocardial infarct size in rats", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 40, no. 10, 1 October 2010 (2010-10-01), pages 893 - 902, XP002791076, ISSN: 0014-2972, DOI: 10.1111/J.1365-2362.2010.02345.X *

Also Published As

Publication number Publication date
CN113395994A (zh) 2021-09-14
WO2020115095A2 (fr) 2020-06-11
EP3890830A2 (fr) 2021-10-13
JP2022510403A (ja) 2022-01-26

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
WO2018112365A3 (fr) Procédés de traitement du cancer colorectal et d'un mélanome en utilisant parabacteroides goldsteinii
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
GB2541571A (en) Pharmaceutical compositions
NZ708727A (en) Conjugate compounds
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
WO2016040952A3 (fr) Benzoimidazol-1,2-yl amides en tant qu'activateurs du canal kv7
GB2568181A (en) Wheat
MA48939B1 (fr) Compositions comprenant des souches bactériennes
PH12021550122A1 (en) Solubilized apyrases, methods and use
WO2016130581A8 (fr) Polythérapie anticancéreuse
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
WO2016109002A3 (fr) Méthodes et compositions pour le traitement de troubles liés à l'irradiation
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
AU2020378127A8 (en) Compounds as CD73 inhibitors
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
AU2015267160A8 (en) Methods and compositions for preventing ischemia reperfusion injury in organs
PH12019502915A1 (en) Immunogenic compositions
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
MX2019009293A (es) Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19816630

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021531704

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019816630

Country of ref document: EP

Effective date: 20210705